In a significant advancement for cancer treatment, researchers from the Mass General Brigham Cancer Institute have demonstrated that targeted radiation therapy can enhance the quality of life for patients with brain metastases. This finding comes from a Phase 3 randomized trial, which revealed that stereotactic radiation therapy, aimed at specific tumors, resulted in improved cognitive outcomes and reduced symptom burden compared to traditional whole brain radiation.
The study, published in JAMA, involved 196 patients diagnosed with brain metastases, a condition where cancer spreads to the brain. Participants had between five and 20 tumors. The trial compared the effects of stereotactic radiation with those of hippocampal-avoidance whole brain radiation, a technique designed to protect the area of the brain responsible for learning and memory.
Ayal Aizer, MD, MHS, who serves as the Director of Central Nervous System Radiation Oncology at Brigham and Women’s Hospital, emphasized the importance of quality of life for patients facing brain tumors. “These results show that expanding the use of stereotactic radiation could minimize patients’ symptom burden and help preserve day-to-day functioning and cognitive abilities,” he stated.
Previous research indicated that for patients with four or fewer brain tumors, stereotactic radiation improves cognitive function without compromising long-term survival. Despite this, patients with a larger number of metastases often receive whole brain radiation. The recent study addressed this gap, offering a more effective treatment option.
The trial’s findings highlighted that patients receiving stereotactic radiation experienced notable improvements in symptom severity and daily functionality six months post-treatment. In contrast, those who underwent hippocampal-avoidance whole brain radiation showed a deterioration in their scores. The study employed a scoring system to evaluate the severity of symptoms and their impact on daily life.
Beyond symptom relief, patients treated with stereotactic radiation displayed a better overall performance status, enabling them to maintain independence in daily activities. Cognitive assessments further demonstrated that these patients outperformed their counterparts who received hippocampal-avoidance whole brain radiation. Interestingly, the median survival rates between the two groups did not significantly differ.
While the study revealed that new brain tumors occurred more frequently among patients receiving stereotactic radiation (45% compared to 24% for whole brain radiation within one year), most new metastases were either treated with follow-up stereotactic radiation or did not require additional intervention. Notably, only 3.2% of patients in the stereotactic group experienced a recurrence of a treated tumor, contrasting with a 39.5% recurrence rate among those who underwent hippocampal-avoidance whole brain radiation. Additionally, approximately 9% of the stereotactic group ultimately required whole brain radiation for new tumors, indicating that this approach often allowed patients to avoid such treatment altogether.
The researchers acknowledged limitations within the study, particularly the inability to blind investigators to treatment assignment. Furthermore, high mortality rates among patients with multiple brain tumors may have influenced the data analysis.
The study included contributions from several co-authors, including Ivy Ricca, Marciana Johnson, and Beverly Spicer, among others. Funding for the trial was provided by Varian, a subsidiary of Siemens Healthineers, with Aizer reporting research support from the company.
This groundbreaking research paves the way for improved treatment strategies for patients with brain metastases, potentially enhancing their quality of life and cognitive function while managing the disease effectively.
